Premium
A comparative study of methyldopa and labetalol in the treatment of hypertension.
Author(s) -
Sanders GL,
Davies DM,
Gales GM,
Rao JG,
Rawlins MD,
Routledge PA
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb04771.x
Subject(s) - labetalol , methyldopa , medicine , pharmacology , blood pressure
1 Twenty patients with essential hypertension completed a double‐blind, dose‐tritrated, cross‐over comparison of methyldopa and labetalol. 2 Average lying BPs (systolic/diastolic) were reduced by 28/15 mmHg with methyldopa and by 23/15 mmHg with labetalol. 3 Average standing BPs (systolic/diastolic) were reduced by 29/14 mmHg with methyldopa and by 29/15 mmHg with labetalol. 4 Both lying and standing heart rates were reduced with labetalol. 5 It is concluded that the antihypertensive properties of labetalol and methyldopa are similar but that larger patient populations are needed to study the relative incidence of subjective adverse effects.